Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

William Gartner of GCDx denies any connection to RXPC.



Dear Mr. Gartner,

I am intrigued by your recent press release about offering a new Lung Cancer Test.

How do you get your financing? Is there an opportunity for a private investor like me to invest, and if so, how would I accomplish that?

In researching GCDx, I am finding several rumors on the internet (particularly on InvestorsHub.com) that your company is merging with, or taking over, Radient Pharmaceuticals and/or Provista Diagnostics. Is there any truth to that rumor? What is your current business relationship with Radient Pharmaceuticals and Provista Diagnostics? Do you own RXPC stock?

I am concerned that Radient might be carrying a lot of debt -- if you are involved with taking over or merging with Radient, what kind of debt responsibilities are you incurring, and if I invest in your company, how would I know that my money is not going towards paying off Radient's debt?

Finally -- do you have any patents or patent applications for The Lung Cancer Test for Early Detection?

Thank you for your time,



AND HERE IS HIS REPLY:


Good morning,

Before I answer all of your questions, I need to know more about you, especially whether or not you are a qualified investor under Rule 144. I will say this to clear up that very old rumor. We have no connection whatsoever with Radient Pharmaceutical in any way – company-wise or personally.


Do you represent a firm or is this personal? We must be very careful to comply with all of the regulations.



Regards,



William Gartner

President and CEO

Global Cancer Diagnostics Inc.

2343 W. University Dr.

Suite 105

Tempe, Arizona 85281 USA

602-908-9604 Office

602-300-4901 Cell